Prehabilitation in Gynaecological Cancer Patients
Recruiting
Phase 3
Interventional Study
Ovarian Cancer
Ovarian Cancer Stage III
Ovarian Cancer Stage IV
Endometrial Cancer
Frailty
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 85
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 64 (estimated)
- Sponsor
- Charles University, Czech Republic · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Prehabilitation refers to interventions aiming to improve patients' resilience and functional capacity before a known stressful event, e.g., scheduled surgery. These interventions usually consist of physical activity and psychological and nutritional support. There is substantial evidence of the positive effect of multimodal prehabilitation among patients treated surgically for non-gynaecological …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion criteria
Two groups of patients will be eligible for the trial:
i) Epithelial ovarian cancer patients referred for NACT: a) FIGO stage III or IV disease; b) Patient is not a candidate for primary debulking surgery; c) Patient is a suitable candidate for standard of care combined chemothe…
Contacts